All Stories

  1. Radioligands Targeting the Purinergic P2X Receptors

    Article • Cells, June 2025, MDPI AG

    Professor Diego Dal Ben

  2. A2A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatment

    Article • European Journal of Pharmaceutical Sciences, April 2025, Elsevier

    Professor Diego Dal Ben

  3. A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson’s Disease

    Article • Cells, February 2025, MDPI AG

    Professor Diego Dal Ben

  4. Chaga Mushroom Triterpenoids Inhibit Dihydrofolate Reductase and Act Synergistically with Conventional Therapies in Breast Cancer

    Article • Biomolecules, November 2024, MDPI AG

    Professor Diego Dal Ben

  5. Dual Anta-Inhibitors Targeting Protein Kinase CK1δ and A2A Adenosine Receptor Useful in Neurodegenerative Disorders

    Article • Molecules, June 2023, MDPI AG

    Professor Diego Dal Ben

  6. Machine Learning Scoring Functions for Drug Discovery from Experimental and Computer-Generated Protein–Ligand Structures: Towards Per-Target Scoring Functions

    Article • Molecules, February 2023, MDPI AG

    Professor Diego Dal Ben

  7. “Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies

    Article • Pharmaceuticals, January 2023, MDPI AG

    Professor Diego Dal Ben

  8. 4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives

    Article • Pharmaceuticals, April 2022, MDPI AG

    Professor Diego Dal Ben

  9. A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?

    Article • Molecules, April 2022, MDPI AG

    Professor Diego Dal Ben

  10. A patent review of adenosine A2Breceptor antagonists (2016-present)

    Article • Expert Opinion on Therapeutic Patents, April 2022, Taylor & Francis

    Professor Diego Dal Ben

  11. A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity

    Article • Pharmaceuticals, January 2022, MDPI AG

    Professor Diego Dal Ben

  12. Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives with High Affinity for Both the Adenosine A1 and A2A Receptors, and Efficacy in Animal Models of Depression

    Article • Pharmaceuticals, July 2021, MDPI AG

    Professor Diego Dal Ben

  13. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

    Article • Neuropharmacology, June 2021, Elsevier

    Professor Diego Dal Ben

  14. P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications

    Article • Frontiers in Pharmacology, April 2021, Frontiers

    Professor Diego Dal Ben

  15. Combined Therapy of A1AR Agonists and A2AAR Antagonists in Neuroinflammation

    Article • Molecules, February 2021, MDPI AG

    Professor Diego Dal Ben

  16. Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents

    Article • European Journal of Medicinal Chemistry, September 2020, Elsevier

    Professor Diego Dal Ben

  17. Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists

    Article • Cells, July 2020, MDPI AG

    Professor Diego Dal Ben

  18. The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis

    Article • Cells, June 2020, MDPI AG

    Professor Diego Dal Ben

  19. New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists

    Article • Bioorganic & Medicinal Chemistry Letters, June 2020, Elsevier

    Professor Diego Dal Ben

  20. Approaches for designing and discovering purinergic drugs for gastrointestinal diseases

    Article • Expert Opinion on Drug Discovery, March 2020, Taylor & Francis

    Professor Diego Dal Ben

  21. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications

    Article • Expert Opinion on Therapeutic Patents, November 2019, Taylor & Francis

    Professor Diego Dal Ben

  22. New A2A adenosine receptor antagonists: a structure-based upside-down interaction in the receptor cavity

    Article • Bioorganic Chemistry, November 2019, Elsevier

    Professor Diego Dal Ben

  23. Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors. Ranging from Pan Ligands to Combined A1/A2B Partial Agonists

    Article • Pharmaceuticals, October 2019, MDPI AG

    Professor Diego Dal Ben

  24. Non-Nucleoside Agonists of the Adenosine Receptors: An Overview

    Article • Pharmaceuticals, October 2019, MDPI AG

    Professor Diego Dal Ben

  25. Antioxidant-Conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain

    Article • Journal of Medicinal Chemistry, August 2019, American Chemical Society (ACS)

    Professor Diego Dal Ben

  26. New sensible method to quantize the intestinal absorption of receptor ligands

    Article • Bioorganic & Medicinal Chemistry, August 2019, Elsevier

    Professor Diego Dal Ben

  27. Modifications on the Amino-3,5-dicyanopyridine Core To Obtain Multifaceted Adenosine Receptor Ligands with Antineuropathic Activity

    Article • Journal of Medicinal Chemistry, July 2019, American Chemical Society (ACS)

    Professor Diego Dal Ben

  28. Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells

    Article • Bioorganic Chemistry, June 2019, Elsevier

    Professor Diego Dal Ben

  29. Neuroprotective potential of adenosine A 1 receptor partial agonists in experimental models of cerebral ischemia

    Article • Journal of Neurochemistry, February 2019, Wiley

    Professor Diego Dal Ben

  30. Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity

    Article • Bioorganic & Medicinal Chemistry Letters, February 2019, Elsevier

    Professor Diego Dal Ben

  31. GPR17 receptor modulators and their therapeutic implications: review of recent patents

    Article • Expert Opinion on Therapeutic Patents, January 2019, Taylor & Francis

    Gabriella Marucci, Professor Diego Dal Ben

  32. Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists

    Article • ACS Medicinal Chemistry Letters, December 2018, American Chemical Society (ACS)

    Professor Diego Dal Ben

  33. Emerging Roles of Purinergic Signaling in Diabetes

    Article • Medicinal Chemistry, July 2018, Bentham Science Publishers

    Professor Diego Dal Ben, Professor Elena Adinolfi

  34. Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA

    Article • European Journal of Pharmaceutical Sciences, June 2018, Elsevier

    Professor Diego Dal Ben

  35. Development of novel pyridazinone-based adenosine receptor ligands

    Article • Bioorganic & Medicinal Chemistry Letters, May 2018, Elsevier

    Professor Diego Dal Ben

  36. New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases

    Article • European Journal of Medicinal Chemistry, May 2018, Elsevier

    Professor Diego Dal Ben

  37. The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor

    Article • European Journal of Medicinal Chemistry, April 2018, Elsevier

    Professor Diego Dal Ben

  38. Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases

    Article • Frontiers in Pharmacology, March 2018, Frontiers

    Professor Diego Dal Ben

  39. Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A 2A adenosine receptor binding site

    Article • Scientific Reports, July 2017, Nature

    Dr Kenneth A. Jacobson, Professor Diego Dal Ben

  40. The P2X7 Receptor in Infection and Inflammation

    Article • Immunity, July 2017, Elsevier

    Professor Diego Dal Ben

  41. The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2AReceptor Subtype

    Article • Journal of Medicinal Chemistry, June 2017, American Chemical Society (ACS)

    Professor Diego Dal Ben

  42. Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7

    Article • EJNMMI Research, April 2017, Springer Science + Business Media

    Professor Diego Dal Ben

  43. Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects

    Article • Fitoterapia, March 2017, Elsevier

    Luciano Barboni, Professor Diego Dal Ben

  44. Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes

    Article • European Journal of Medicinal Chemistry, January 2017, Elsevier

    Professor Diego Dal Ben

  45. Overview on Radiolabel-Free in vitro Assays for GPCRs

    Article • Mini-Reviews in Medicinal Chemistry, November 2016, Bentham Science Publishers

    Gabriella Marucci, Professor Diego Dal Ben

  46. The G Protein‐Coupled Receptor GPR17: Overview and Update

    Article • ChemMedChem, November 2016, Wiley

    Professor Diego Dal Ben

  47. 2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents

    Article • Purinergic Signalling, October 2016, Springer Science + Business Media

    Professor Diego Dal Ben

  48. Simulation and Comparative Analysis of Different Binding Modes of Non‐nucleoside Agonists at the A2AAdenosine Receptor

    Article • Molecular Informatics, June 2016, Wiley

    Professor Diego Dal Ben

  49. Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors

    Article • Bioorganic & Medicinal Chemistry, June 2016, Elsevier

    Professor Diego Dal Ben

  50. A Novel Class of Dopamine D4Receptor Ligands Bearing an Imidazoline Nucleus

    Article • ChemMedChem, March 2016, Wiley

    Sergi Ferre, Professor Diego Dal Ben

  51. new insights on the therapeutic potential of P2X7 antagonists in human pathology

    Article • January 2016, Elsevier

    Professor Elena Adinolfi, Professor Diego Dal Ben

  52. Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation

    Article • European Journal of Medicinal Chemistry, May 2015, Elsevier

    Professor Diego Dal Ben

  53. Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists

    Article • Current Medicinal Chemistry, February 2015, Bentham Science Publishers

    Professor Diego Dal Ben

  54. Editorial (Thematic Issue: Purinergic P2X Receptors: Physiological and Pathological Roles and Potential as Therapeutic Targets)

    Article • Current Medicinal Chemistry, February 2015, Bentham Science Publishers

    Professor Diego Dal Ben, Professor Elena Adinolfi

  55. New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists

    Article • MedChemComm, January 2015, Royal Society of Chemistry

    Professor Diego Dal Ben

  56. Purinergic P2X receptors: Structural models and analysis of ligand-target interaction

    Article • European Journal of Medicinal Chemistry, January 2015, Elsevier

    Professor Diego Dal Ben

  57. 1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies

    Article • Bioorganic & Medicinal Chemistry, January 2015, Elsevier

    Professor Diego Dal Ben

  58. Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2Aand A3adenosine receptor agonists

    Article • Journal of Pharmacy and Pharmacology, April 2014, Wiley

    Dr Ioanna Andreadou, Professor Diego Dal Ben

  59. Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines

    Article • The Scientific World JOURNAL, January 2014, Hindawi Publishing Corporation

    Professor Diego Dal Ben

  60. Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch

    Article • Biochemical Pharmacology, January 2014, Elsevier

    Professor Diego Dal Ben

  61. 8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands

    Article • European Journal of Medicinal Chemistry, December 2013, Elsevier

    Professor Diego Dal Ben

  62. Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists

    Article • European Journal of Medicinal Chemistry, July 2013, Elsevier

    Professor Diego Dal Ben

  63. Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: Synthesis, structure–affinity relationships and molecular modeling studies

    Article • Bioorganic & Medicinal Chemistry, January 2013, Elsevier

    Professor Diego Dal Ben

  64. Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor

    Article • In Silico Pharmacology, January 2013, Springer Science + Business Media

    Professor Diego Dal Ben

  65. ChemInform Abstract: New 9-Methyl-8-(4-hydroxyphenyl)adenine Derivatives as A1Adenosine Receptor Antagonists.

    Article • ChemInform, February 2012, Wiley

    Professor Diego Dal Ben

  66. ChemInform Abstract: Neuropeptide S Receptor: Recent Updates on Nonpeptide Antagonist Discovery

    Article • ChemInform, August 2011, Wiley

    Professor Diego Dal Ben

  67. Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17

    Article • Purinergic Signalling, July 2011, Springer Science + Business Media

    Professor Diego Dal Ben

  68. Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1

    Article • Analytical Biochemistry, July 2011, Elsevier

    Professor Diego Dal Ben

  69. Synthesis, structure–affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists

    Article • Bioorganic & Medicinal Chemistry, June 2011, Elsevier

    Professor Diego Dal Ben

  70. Inside Cover: Evidence for the Existence of a Specific G Protein-Coupled Receptor Activated by Guanosine (ChemMedChem 6/2011)

    Article • ChemMedChem, May 2011, Wiley

    Professor Diego Dal Ben

  71. Evidence for the Existence of a Specific G Protein-Coupled Receptor Activated by Guanosine

    Article • ChemMedChem, April 2011, Wiley

    Professor Diego Dal Ben

  72. The Importance of Alkynyl Chain Presence for the Activity of Adenine Nucleosides/Nucleotides on Purinergic Receptors

    Article • Current Medicinal Chemistry, April 2011, Bentham Science Publishers

    Professor Diego Dal Ben

  73. Neuropeptide S Receptor: Recent Updates on Nonpeptide Antagonist Discovery

    Article • ChemMedChem, March 2011, Wiley

    Professor Diego Dal Ben

  74. New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists

    Article • Collection of Czechoslovak Chemical Communications, January 2011, Institute of Organic Chemistry & Biochemistry

    Professor Diego Dal Ben

  75. Molecular modeling study on potent and selective adenosine A3 receptor agonists

    Article • Bioorganic & Medicinal Chemistry, November 2010, Elsevier

    Professor Diego Dal Ben

  76. Adenosine Receptor Modeling: What Does the A2A Crystal Structure Tell Us?

    Article • Current Topics in Medicinal Chemistry, July 2010, Bentham Science Publishers

    Professor Diego Dal Ben

  77. Molecular Modeling Studies on the Human Neuropeptide S Receptor and Its Antagonists

    Article • ChemMedChem, February 2010, Wiley

    Professor Diego Dal Ben

  78. Synthesis and Biological Evaluation of 2-Alkynyl- N 6 -methyl-5′- N -methylcarboxamidoadenosine Derivatives as Potent and Highly Selective Agonists for the Human Adenosine A 3 Receptor ‡

    Article • Journal of Medicinal Chemistry, December 2009, American Chemical Society (ACS)

    Professor Diego Dal Ben

  79. Adenine-Based Acyclic Nucleotides as Novel P2X 3 Receptor Ligands

    Article • Journal of Medicinal Chemistry, August 2009, American Chemical Society (ACS)

    Professor Diego Dal Ben

  80. Adenosine A2AReceptor Antagonists: New 8-Substituted 9-Ethyladenines as Tools for in vivo Rat Models of Parkinson's Disease

    Article • ChemMedChem, June 2009, Wiley

    Professor Diego Dal Ben

  81. 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands

    Article • Bioorganic & Medicinal Chemistry, April 2009, Elsevier

    Professor Diego Dal Ben

  82. Identification of α1-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens

    Article • European Journal of Pharmacology, January 2009, Elsevier

    Professor Diego Dal Ben

  83. Novel potent and highly selective human A3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: Molecular docking analysis and pharmacological studies

    Article • Bioorganic & Medicinal Chemistry, January 2009, Elsevier

    Professor Diego Dal Ben

  84. Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs

    Article • Bioorganic & Medicinal Chemistry, September 2008, Elsevier

    Professor Diego Dal Ben

  85. ChemInform Abstract: Synthesis and Biological Activity of Trisubstituted Adenines as A2AAdenosine Receptor Antagonists

    Article • ChemInform, March 2008, Wiley

    Professor Diego Dal Ben

  86. Synthesis and Antitumor Evaluation of Bis Aza-anthracene-9,10-diones and Bis Aza-anthrapyrazole-6-ones

    Article • Journal of Medicinal Chemistry, February 2008, American Chemical Society (ACS)

    Professor Diego Dal Ben

  87. Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives

    Article • Bioorganic & Medicinal Chemistry, January 2008, Elsevier

    Professor Claudia Sissi, Professor Diego Dal Ben

  88. Synthesis and Stability Studies of 2′,3′,5′-tri-O-Acetyl-2-Amino(-N6-Cyclopentyl)-1-Deazaadenosines

    Article • Nucleosides Nucleotides & Nucleic Acids, November 2007, Taylor & Francis

    Professor Diego Dal Ben

  89. Synthesis and Biological Activity of Trisubstituted Adenines as A2AAdenosine Receptor Antagonists

    Article • Nucleosides Nucleotides & Nucleic Acids, November 2007, Taylor & Francis

    Professor Diego Dal Ben

  90. DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation

    Article • Current Pharmaceutical Design, September 2007, Bentham Science Publishers

    Professor Diego Dal Ben

  91. New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile

    Article • Purinergic Signalling, September 2007, Springer Science + Business Media

    Professor Diego Dal Ben

  92. Highlights on the Development of A2A Adenosine Receptor Agonists and Antagonists

    Article • ChemInform, June 2007, Wiley

    Professor Diego Dal Ben

  93. Highlights on the Development of A2A Adenosine Receptor Agonists and Antagonists

    Article • ChemMedChem, March 2007, Wiley

    Professor Diego Dal Ben

  94. N 6 -Methoxy-2-alkynyladenosine Derivatives as Highly Potent and Selective Ligands at the Human A 3 Adenosine Receptor

    Article • Journal of Medicinal Chemistry, March 2007, American Chemical Society (ACS)

    Professor Diego Dal Ben

  95. Antiviral Properties of Deazaadenine Nucleoside Derivatives

    Article • Current Medicinal Chemistry, December 2006, Bentham Science Publishers

    Professor Diego Dal Ben

  96. Erratum to: Molecular modelling study of 2-phenylethynyladenosine (PEAdo) derivatives as highly selective A3 adenosine receptor ligands

    Article • Purinergic Signalling, October 2006, Springer Science + Business Media

    Professor Diego Dal Ben

  97. Molecular modelling study of 2-phenylethynyladenosine (PEAdo) derivatives as highly selective A3 adenosine receptor ligands

    Article • Purinergic Signalling, August 2006, Springer Science + Business Media

    Professor Diego Dal Ben

  98. GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support

    Article • Journal of the Iranian Chemical Society, September 2005, Springer Science + Business Media

    Professor Diego Dal Ben

  99. Interaction Model for Anthracycline Activity against DNA Topoisomerase II †

    Article • Biochemistry, June 2004, American Chemical Society (ACS)

    Professor Diego Dal Ben

  100. Toward the rational design of protein kinase casein kinase-2 inhibitors

    Article • Pharmacology & Therapeutics, February 2002, Elsevier

    Professor Diego Dal Ben